Evidence map›Paper›PMID 20886085›Full record

ArticlePloS one2010

Features of cryptic promoters and their varied reliance on bromodomain-containing factors.

Samantha G Pattenden, Madelaine M Gogol, Jerry L Workman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Samantha G PattendenStowers Institute for Medical Research, Kansas City, Missouri, United States of America.
Madelaine M Gogol
Jerry L Workman
Stowers Institute for Medical Research · US

Funding

Mechanisms of Transcriptional Regulation in ChromatinR37GM047867 · NIGMS · STOWERS INSTITUTE FOR MEDICAL RESEARCH · PI WORKMAN, JERRY L · 2001 to 2010
$3.4M
NIGMS NIH HHS R37 GM047867NIGMS NIH HHS R37 GM47867
6 · The paper itself

Abstract

The Set2-Rpd3S pathway is important for the control of transcription memory. Mutation of components of this pathway results in cryptic transcription initiation within the coding region of approximately 30% of yeast genes. Specifically, deletion of the Set2 histone methyltransferase or Rco1, a component of the Rpd3S histone deacetylase complex leads to hyperacetylation of certain open reading frames (ORFs). We used this mutant as a system to study the role of histone modifications and co-activator recruitment in preinitiation complex (PIC) formation. Specifically, we looked at the dependence of promoters on the bromodomain-containing RSC complex and the Bdf1 protein. We found that the dependence of cryptic promoters for these proteins varied. Overall, our data indicate that cryptic promoters are independently regulated, and their activation is dependent on factors that govern gene activation at canonical promoters.

Indexed as

Gene Expression Regulation, FungalPromoter Regions, GeneticAcetylationChromosomal Proteins, Non-HistoneHistone DeacetylasesHistonesProtein Structure, TertiarySaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsChromosomal Proteins, Non-HistoneHistone DeacetylasesHistonesRPD3 protein, S cerevisiaeRSC1 protein, S cerevisiaeSaccharomyces cerevisiae Proteins

Identifiers

PMID20886085
PMCPMC2944879
OpenAlexW2047925661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.